Welcome to our dedicated page for Exp World Holdin SEC filings (Ticker: EXPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
eXp World Holdings鈥� cloud brokerage model turns physical offices into a fully virtual campus, so its SEC disclosures focus heavily on agent commission splits, equity incentives, and technology costs. If you have ever searched 鈥渆Xp World Holdings SEC filings explained simply,鈥� this page answers that need by translating complex statements into clear insights.
Stock Titan鈥檚 AI reviews every 10-K, 10-Q, 8-K, and Form 4 the moment they post to EDGAR. Want the eXp World Holdings quarterly earnings report 10-Q filing without wading through accounting jargon? Our summaries spotlight agent count trends, revenue share payouts, and margin shifts. Curious about leadership activity? Receive eXp World Holdings Form 4 insider transactions real-time alerts that detail each executive stock move, helping you monitor eXp World Holdings executive stock transactions Form 4 before the market reacts.
Beyond numbers, our platform links filing sections to practical questions investors ask every quarter:
- 鈥淗ow are stock-based awards affecting dilution?鈥� 鈥� answered in the eXp World Holdings annual report 10-K simplified.
- 鈥淒id leadership sell shares before big announcements?鈥� 鈥� tracked through eXp World Holdings insider trading Form 4 transactions.
- 鈥淲hat material events could move the share price?鈥� 鈥� see the eXp World Holdings 8-K material events explained.
- 鈥淗ow is executive pay structured?鈥� 鈥� outlined in the eXp World Holdings proxy statement executive compensation.
Form 3 Overview: The filing discloses the initial beneficial ownership of Joshua T. Brumm, who became Chief Executive Officer and Director of Crescent Biopharma, Inc. following a two-step merger completed on 13 Jun 2025. At the Effective Time, GlycoMimetics, Inc. merged with Crescent Biopharma and simultaneously changed its corporate name to Crescent Biopharma, Inc., then converted from a Delaware corporation to a Cayman Islands exempted company on 16 Jun 2025.
Equity Holdings:
- 268,400 ordinary shares held directly via restricted stock units (RSUs) that vest 25 % on 17 Mar 2026 and 6.25 % quarterly thereafter through 17 Mar 2029.
- 805,200 stock options with a $6.16 exercise price, vesting 25 % on 17 Mar 2026 and monthly thereafter until 17 Mar 2029.
The filing confirms that all Pre-Merger Crescent equity awards automatically converted into equivalent Cayman ordinary-share instruments under identical terms. Brumm filed as a single reporting person and retains direct ownership of all disclosed securities.
Investor Relevance: The document affirms completion of the M&A transaction, finalizes the company鈥檚 redomiciling process, and reveals executive equity incentives that could add up to 1.07 million shares to the future float if fully vested and exercised.
Everi Holdings Inc. (EVRI) filed Post-Effective Amendment No. 1 to twelve prior Form S-8 registration statements covering an aggregate of approximately 48.6 million shares of common stock reserved for various equity compensation plans dating back to 2006. The amendment formally deregisters all unsold shares under those statements.
The action follows the 1 July 2025 closing of a multi-party transaction in which funds managed by affiliates of Apollo Global Management (through Voyager Parent, LLC) simultaneously acquired Everi and International Game Technology PLC鈥檚 Gaming & Digital business:
- IGT transferred its Gaming & Digital assets to Ignite Rotate LLC ("Spinco") and related liabilities (the 鈥淪eparation鈥�).
- Buyer purchased all Spinco units and IGT Canada Solutions ULC shares.
- Voyager Merger Sub, Inc. merged with and into Everi, making Everi a wholly owned subsidiary of Buyer (the 鈥淢erger鈥�).
Because Everi鈥檚 common stock will be delisted and deregistered under Section 12(b) of the Exchange Act, the company is terminating all outstanding securities offerings. Upon effectiveness of this filing, no shares remain registered for sale under the referenced S-8 statements.
Worthington Enterprises, Inc. (WOR) 鈥� Form 4 filing dated 06/30/2025
Controller Kevin J. Chan reported two routine equity-based transactions that increased his beneficial ownership without any open-market purchases or sales:
- Restricted stock award: 960 common shares granted on 06/26/2025 at $0.00 under the 2024 Long-Term Incentive Plan. The shares will vest on the third anniversary of the grant date. Direct holdings rose to 6,549 shares after the grant.
- Phantom stock credit: 3.69 theoretical common shares added on 06/27/2025 at a reference price of $63.81 through the company鈥檚 deferred compensation plan, lifting the phantom balance to 125.63 units. Phantom stock tracks WOR one-for-one and is payable only in common shares upon distribution.
Chan also reports 2,848.45 common shares held indirectly in his 401(k) plan as of 06/27/2025. No dispositions, sales, or 10b5-1 plan transactions were disclosed.
The filing signals ongoing equity-based compensation and maintains insider alignment, but the share amounts are small relative to WOR鈥檚 public float and therefore unlikely to be market-moving.
FAQ
What is the current stock price of Exp World Holdin (EXPI)?
What is the market cap of Exp World Holdin (EXPI)?
What is the core business of eXp World Holdings?
How does the company support its agents?
What technology innovations does eXp World Holdings utilize?
In which markets does eXp World Holdings operate?
What differentiates eXp World Holdings from traditional real estate brokerages?
What are the company's primary technology products and services?
How does eXp World Holdings maintain its competitive edge?
Does eXp World Holdings offer support beyond property transactions?
